Want to join the conversation?
Global biopharmaceutical leader $BXLT announced the approval of OBIZUR from Health Canada to treat patients with acquired hemophilia A, a rare life-threatening bleeding disorder. Brian, EVP quoted "We look forward to introducing this treatment for hemophilia community in Canada & continuing our efforts to reduce the burden of bleeding disorders."
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.